LY2228820

Phase 2Small molecule

Eli Lilly

LY2228820 is one of 113 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Ovarian CancerActive, not recruiting

GlioblastomaActive, not recruiting

Cardiovascular DiseasePhase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

22 2

Trodelvy

Gilead

Phase 3

3 3

Vepesid

AAvyxa

Phase 3

6 4

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 5

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 6

H1 Receptor Antagonist

Merck & Co.

Phase 3

1 7

SHR-A1921

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 8

Gleolan

NNX Development Corp

Phase 3

1 9

EC20

EEndocyte

Phase 3

1 10

EC145

EEndocyte

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Study LY2228820 for Recurrent Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01663857·118 enrolled

Advanced Cancer1 trial

A Study of LY2228820 in Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01393990·89 enrolled

Glioblastoma1 trial

Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

Completed·CCentre Jean Perrin·Phase 1/2·NCT02364206·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LY2228820. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY2228820 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY2228820. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY2228820

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Advanced Cancer1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News